Why isn't Mounjaro working for me?

Are you still in the early weeks of treatment?

The single most common reason people feel Mounjaro isn't working is that they are still in the dose-adjustment phase. Treatment begins at 2.5 mg, and that first pen's job is to let your body adapt to the medicine, the nausea and digestive changes people sometimes notice are a sign it is active, not that it is working therapeutically. The tirzepatide dosing schedule typically moves through 2.5 mg, 5 mg, 7.5 mg and beyond in roughly four-week steps, and meaningful, consistent appetite reduction tends to become noticeable from the 5 mg or 7.5 mg stages for most people.

This matters because many people compare their experience at week three to trial results that were measured at week 72. The SURMOUNT-1 trial (involving more than 2,500 adults over 72 weeks) reported average weight reduction of around 20–21% at the 15 mg maintenance dose, published in the New England Journal of Medicine. That is a long-horizon figure. Expecting the same trajectory in the first month sets an unrealistic baseline.

Patience is not a passive strategy here. If you are a few weeks in and wondering why tirzepatide does not seem to be working for you yet, appetite has barely changed at the current dose, that is worth raising with your prescriber at the next review rather than assuming the medicine is failing you. It may simply mean you are ready to titrate.

Could something be interfering with how the medicine works?

Several practical factors can blunt tirzepatide's effect without anyone realising. Injection technique is one, the pen should be held firmly against the skin at the chosen site (abdomen, thigh or upper arm) until the injection is complete, and rotating sites each week matters. Using the same spot repeatedly can affect absorption over time.

Storage is another quiet culprit. Mounjaro pens must be refrigerated between 2–8°C; a pen left in a bag in a warm car, or placed in the freezer by mistake, may degrade. The Mounjaro SmPC on the eMC gives precise guidance on the limited window for room-temperature storage, always check the leaflet rather than guessing. If a pen has been stored incorrectly it should not be used.

Diet composition also matters in a way that surprises some people. Tirzepatide reduces appetite strongly for many, but if calorie intake has not actually fallen (because highly palatable, calorie-dense foods are still being eaten in smaller volume) weight loss stalls. Alcohol, which is calorie-dense and rarely registers as food, is a common blind spot. None of this is about willpower; it is about understanding what the medicine does and does not change on its own.

If you are wondering whether cost or access is affecting whether you can stay consistent with treatment, our Mounjaro price comparison guide explains what private treatment typically costs and what a legitimate price includes.

What does a genuine plateau look like, and when should you talk to your prescriber?

A plateau on the scales for two or three weeks is normal physiology, not a treatment failure. The body adjusts to a lower intake by temporarily reducing its metabolic rate, and fluid shifts (particularly around exercise) can mask fat loss on weekly weigh-ins. This is worth knowing because people sometimes lose confidence and reduce their dose or stop treatment at precisely the point where they are about to break through a flat period.

A genuine plateau worth investigating is different: six months or more on the highest tolerated dose with less than 5% change in body weight. NICE's appraisal of tirzepatide, TA1026, uses this threshold as the clinical marker for reviewing whether to continue, a useful benchmark for your own thinking too. Some people reach a biological ceiling at a lower dose than expected; others find that a dose increase, once clinically appropriate, restarts progress.

People who have switched from another GLP-1 medicine sometimes find the transition feels slow, as the body needs time to respond to a different mechanism. If you have been at a stable dose for several months and are concerned that Mounjaro has stopped working for you, that conversation belongs with a prescriber who can look at your full picture, not a forum.

Is there something else going on that might need attention?

Occasionally, the reason Mounjaro isn't working is unrelated to the medicine itself. Unmanaged thyroid conditions, particularly hypothyroidism, make weight loss significantly harder and are common enough that they are worth checking if you have not had bloods done recently. Chronic sleep deprivation disrupts the same hunger hormones that tirzepatide targets, which can partially counteract its effect. High stress levels drive cortisol, which encourages fat retention and can override appetite suppression.

These are not reasons to abandon treatment, they are reasons to make sure the conditions for treatment to succeed are in place. A prescriber reviewing your progress can consider whether any of these factors are relevant and whether anything else needs investigation. If you have broader questions about how tirzepatide works and what affects it, our tirzepatide information page covers the mechanism in detail.

If you are experiencing an unexpected physical symptom rather than simply slow progress, that is a separate concern. Our page on fainting on Mounjaro covers one of the symptoms people sometimes report, and for anything that feels urgent, your GP or 111 should be the first call.

A prescriber review is the right place to take all of this. If you have not yet started treatment or want a clinical assessment of your current position, you can check your eligibility with our prescribers through a free consultation, reviewed the same day by a real clinician, not automated software.